X0306 4 2023-01-19 1 0001325879 AVEO PHARMACEUTICALS, INC. AVEO 0001210238 BATE KENNETH C/O AVEO PHARMACEUTICALS, INC. 30 WINTER STREET BOSTON MA 02108 1 0 0 0 Common Stock 2023-01-19 4 D 0 375 15.00 D 375 D Stock Option (Right to Buy) 25.90 2023-01-19 4 D 0 1250 D 2023-05-29 Common Stock 1250 0 D Stock Option (Right to Buy) 15.70 2023-01-19 4 D 0 1250 D 2024-06-19 Common Stock 1250 0 D Stock Option (Right to Buy) 16.10 2023-01-19 4 D 0 2515 D 2025-04-02 Common Stock 2515 0 D Stock Option (Right to Buy) 20.00 2023-01-19 4 D 0 2000 D 2025-05-28 Common Stock 2000 0 D Stock Option (Right to Buy) 9.20 2023-01-19 4 D 0 6402 D 2026-05-26 Common Stock 6402 0 D Stock Option (Right to Buy) 7.00 2023-01-19 4 D 0 7785 D 2027-06-21 Common Stock 7785 0 D Stock Option (Right to Buy) 22.70 2023-01-19 4 D 0 4000 D 2028-06-17 Common Stock 4000 0 D Stock Option (Right to Buy) 7.60 2023-01-19 4 D 0 4000 D 2029-06-11 Common Stock 4000 0 D Stock Option (Right to Buy) 7.52 2023-01-19 4 D 0 4000 D 2030-06-09 Common Stock 4000 0 D Stock Option (Right to Buy) 7.27 2023-01-19 4 D 0 12500 D 2031-06-08 Common Stock 12500 0 D Stock Option (Right to Buy) 4.27 2023-01-19 4 D 0 22500 D 2032-06-06 Common Stock 22500 0 D Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration. This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. On January 19, 2022, pursuant to the Agreement and Plan of Merger (as it may be amended from time to time, referred to as the "Merger Agreement"), by and among LG Chem, Ltd. ("Parent"), Acacia acquisition Sub, Inc. ("Merger Sub") and AVEO Pharmaceuticals, Inc. (the "Company"), dated as of October 18, 2022, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of the Company's common stock automatically converted into the right to receive $15.00 per share in cash (the "Merger Consideration"). /s/ Danielle V. Holland, attorney in fact 2023-01-19